论文部分内容阅读
目的:研究大肠癌中检测TopoI表达来选择术后个体化辅助化疗方案的临床意义。方法:将84例大肠癌患者根治术后的石蜡标本行免疫组化检测TopoI的表达情况,根据蛋白检测结果选择患者个体化的化疗方案。未行TopoI检测的同期对照组按传统方法选择化疗方案,对比分析两组患者的无进展生存时间(progress free survival,PFS)、中位生存期(median survival time,MST)和疾病控制率(disease control rate,DCR)。结果:大肠癌组织中TopoI的表达与性别、肿瘤大小、分化程度、肿瘤分期无关,而与年龄有关(P<0.05)。依据TopoI蛋白检测选择化疗方案组中位PFS为7.8个月;对照组中位PFS为7.2个月,两组PFS比较差异有统计学意义[(7.55±1.53)个月vs(6.93±1.62)个月,P<0.05]。实验组的中位生存期为17.2个月,对照组为13.6个月。而且IV期患者实验组疾病控制率显著升高(80.8%vs 52.6%,P<0.05)。结论:通过检测大肠癌术后TopoI的表达来选择个体化的治疗方案,具有重要的临床指导价值。
Objective: To study the clinical significance of TopoI expression in colorectal cancer to select the individualized adjuvant chemotherapy regimen. Methods: The expression of TopoI was detected by immunohistochemistry in 84 cases of patients with colorectal cancer after radical resection. According to the results of protein test, individualized chemotherapy regimen was selected. In the control group without TopoI, the chemotherapy regimens were selected according to the traditional methods. The progression free survival (PFS), median survival time (MST) and disease control rate control rate, DCR). Results: The expression of TopoI in colorectal cancer was not related with sex, tumor size, differentiation degree, tumor stage, but with age (P <0.05). According to the TopoI protein test, the median PFS was 7.8 months in the chemotherapy regimen group and 7.2 months in the control group. There was significant difference in PFS between the two groups [(7.55 ± 1.53) months vs (6.93 ± 1.62) months Month, P <0.05]. The median survival time was 17.2 months in the experimental group and 13.6 months in the control group. Moreover, the disease control rate in the experimental group of stage IV patients was significantly higher (80.8% vs 52.6%, P <0.05). Conclusion: It is an important clinical guideline to select individualized treatment regimen by detecting TopoI expression in colorectal cancer after operation.